CAS No.10262-69-8,Maprotiline Suppliers

Products Categories

Pharmaceutical (22)
Others (9)
Organic Chemicals (5)
Basic Inorganic Chemicals (2)
Reagent (1)

Basic Information

Molecular Structure:
CAS No.:	10262-69-8
Name:	Maprotiline
Article Data:	5

Formula:	C₂₀H₂₃N
Molecular Weight:	277.409
Synonyms:	9,10-Ethanoanthracene-9(10H)-propylamine,N-methyl- (7CI,8CI);Maprotiline;N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine;
EINECS:	233-599-4
Density:	1.081 g/cm³
Melting Point:	92-94°
Boiling Point:	399.615 °C at 760 mmHg
Flash Point:	187.657 °C
Solubility:	833.4ug/L(22.5 oC)
Transport Information:	UN 3249
PSA:	12.03000
LogP:	4.60230

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:36 Page 1 of 1 1

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 10262-69-8

History

Ludiomil (10262-69-8) was developed and has been marketed by the Swiss manufacturer Geigy (now Novartis) since the early 1980s under the brand name Ludiomil. Generics are widely available

Specification

The CAS register number of Maprotiline is 10262-69-8. It also can be called as N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine and the systematic name about this chemical is 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine. The molecular formula about this chemical is C₂₀H₂₃N and the molecular weight is 277.41. Classification code about this chemical are Adrenergic Agents, Adrenergic uptake inhibitors, Antidepressant, Antidepressive Agents, Antidepressive agents, second-generation, Central Nervous System Agents, Drug / Therapeutic Agent, Human Data, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors and Psychotropic Drugs. This chemical is a bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.

Physical properties about Maprotiline are: (1)ACD/LogP: 4.51; (2)ACD/LogD (pH 5.5): 1.41; (3)ACD/LogD (pH 7.4): 1.65; (4)ACD/BCF (pH 5.5): 1.26; (5)ACD/BCF (pH 7.4): 2.2; (6)ACD/KOC (pH 5.5): 5.43; (7)ACD/KOC (pH 7.4): 9.44; (8)#H bond acceptors: 1; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 4; (11)Polar Surface Area: 3.24Å²; (12)Index of Refraction: 1.599; (13)Molar Refractivity: 87.77 cm³; (14)Molar Volume: 256.7 cm³; (15)Polarizability: 34.79x10^-24cm³; (16)Surface Tension: 46.4 dyne/cm; (17)Enthalpy of Vaporization: 65.04 kJ/mol; (18)Boiling Point: 399.6 °C at 760 mmHg; (19)Vapour Pressure: 1.35E-06 mmHg at 25°C.

The Maprotiline is a tetracyclic antidepressant (TeCA). It is a strong norepinephrine reuptake inhibitor with only weak effects on serotonin and dopamine reuptake.it causes a strong initial sedation (first 2 to 3 weeks of therapy) and is therefore indicated to treat agitated patients or those with suicidal risks. It causes anticholinergic side effects with a lower incidence than Amitritypline. Originally, the manufacturer claimed that Maprotiline is better tolerated than other tri-/tetrcyclic drugs. This is not the case because seizures, leukopenia and skin reactions occur more often with Maprotiline than with comparable drugs like Amitriptyline.

The reduction of β-(9 - anthryl) propionic acid can get 9 - (3 - hydroxy-propyl) methylamine, and it can condensation with anthracene to produce β-[(9 - anthryl) propyl] methylamine, then condensation with ethylene to get Maprotiline.

Uses of Maprotiline: it can be used to produce 3-Chlor-2-[N-methyl-3-(9,10-dihydro-9,10-ethano-anthr-9-yl)-propylamino]-1,4-naphthoχnon with 2,3-dichloro-[1,4]naphthoquinone. This reaction will need solvent CH₂Cl₂ with reaction time of 18 hours. The yield is about 65%.

You can still convert the following datas into molecular structure:
(1)SMILES: c1ccc3c(c1)C4c2ccccc2C3(CC4)CCCNC
(2)InChI: InChI=1/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
(3)InChIKey: QSLMDECMDJKHMQ-UHFFFAOYAS
(4)Std. InChI: InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
(5)Std. InChIKey: QSLMDECMDJKHMQ-UHFFFAOYSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	26mg/kg (26mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: COMA VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION	British Medical Journal. Vol. 2, Pg. 260, 1977.
mouse	LD50	intraperitoneal	140mg/kg (140mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 40, Pg. 235, 1983.
mouse	LD50	intravenous	31mg/kg (31mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: ATAXIA	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.
mouse	LD50	oral	660mg/kg (660mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: ATAXIA	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.
rat	LD50	intraperitoneal	105mg/kg (105mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 40, Pg. 235, 1983.
rat	LD50	intravenous	38mg/kg (38mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: ATAXIA BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.
rat	LD50	oral	760mg/kg (760mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: ATAXIA BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980.